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Brugada syndrome is characterised by a typical ECGwith ST segment elevation in the right precordial leads.
Individuals with this condition are susceptible to ventricular arrhythmias and sudden cardiac death. The
principal gene responsible for this syndrome is SCN5A, which encodes the a-subunit of the Nav1.5
voltage-gated sodium channel. Mutations involving other genes have been increasingly reported, but their
contribution to Brugada syndromehas been poorly investigated.Herewe focused on the SCN1Bgene, which
encodes the b1-subunit of the voltage-gated sodium channel and its soluble b1b isoform. SCN1Bmutations
have been associatedwith Brugada syndrome as well as with other cardiac arrhythmias and familial epilepsy.
In this study, we have analysed SCN1B exons (including the alternatively-spliced exon 3A) and 39UTR in 145
unrelated SCN5A-negative patients from a single centre. We took special care to report all identified
variants (including polymorphisms), following the current nomenclature guidelines and considering both
isoforms. We found two known and two novel (and likely deleterious) SCN1B variants. We also found two
novel changes with low evidence of pathogenicity. Our findings contribute more evidence regarding the
occurrence of SCN1B variants in Brugada syndrome, albeit with a low prevalence, which is in agreement
with previous reports.
B
rugada syndrome (BrS) is an arrhythmogenic cardiopathy characterised by a typical ECG pattern with ST
segment elevation in the right precordial leads and a predisposition to malignant events in the absence of
structural heart disease1. The genetic basis of this condition is heterogeneous, and inheritance autosomal
dominant1,2. Due to incomplete penetrance and variable expressivity, however, familial associations often are not
recognised. The first gene identified in association with BrS was SCN5A, which encodes for the a-subunit of the
cardiac voltage-gated sodium channel (Nav1.5)3. Loss-of-function mutations in SCN5A account for an estimated
15% to 30% of BrS cases2,4.
In a minority of patients, mutations have been found in genes encoding subunits of the cardiac calcium or
potassium channels or other proteins involved in the regulation of cardiac sodium current or the maintenance of
the resting membrane potential5.
Crotti and coworkers6 recently reported on the contribution of 12 knownBrS-susceptibility genes in one cohort
of patients. SCN5A was confirmed as the major contributing gene the other 11 genes together accounted for less
than 5% of the cases in the study and also displayed lower penetrance. Consequently, the authors suggest that
routine genetic testing in the case of BrS should be limited to SCN5A, and should be extended to other genes only
in the presence of peculiar features (e.g., to calcium channel subunits in patients presenting with short QT-
associated BrS)6,7.
However, because studies on the minor BrS susceptibility genes are relatively few, it is unclear when testing is
appropriate.
In this study, we focus on the minor BrS susceptibility gene SCN1Bwhose alternatively spliced mRNAs encode
the b1 subunit of the voltage-gated sodium channel (NM_001037, NP_001028, isoform A) and its soluble b1b
isoform (NM_199037, NP_950238 isoform B)8. Both isoforms are expressed in human heart and brain. The
transmembrane b1 subunit is known tomodulate the sodium channel through non-covalent interaction with the
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a subunit. In addition to cardiac excitability, the b1 subunit has
multiple roles involving neural excitability, cell-cell adhesion, cell
migration and neurite outgrowth, and pathfinding9,10. Less is known
about the soluble b1b peptide encoded by the alternative splice vari-
ant retaining intron 311.
SCN1B mutations were originally identified in patients with
genetic epilepsy with febrile seizures plus spectrum disorders
(GEFS1)9,12–14. Subsequently, mutations of SCN1B were found to
be associated with various arrhythmic phenotypes, such as cardiac
conduction disease15, sudden infant death syndrome (SIDS)16, atrial
fibrillation17,18 and long QT syndrome19, thus supporting the role of
b1 and/or b1b in normal cardiac electrical activity.
Screening for SCN1B mutations has been extended through a
variety of studies involving patients from different popula-
tions6,15,16,18,20–22. The current study aims to determine the prevalence
and spectrum of SCN1B genetic variants in 145 unrelated SCN5A–
negative BrS patients recruited at a single centre.
Results
Table 1 shows the twenty observed single nucleotide substitutions
(listed in order of genomic position) and their predicted effects on
either of the two transcripts - SCN1B and SCN1Bb - and the encoded
b1 and/or b1b subunits. Also listed are the incidence of each substi-
tution among the 145 patients and their presence in online database
and literature listings, their conservation among species, as well as in
silico predictions of their pathogenicity. Sixteen of the substitutions
have previously been reported as polymorphisms or as rare genetic
variants.
Two of the previously undescribed changes and two of the known
changes are predicted to affect only one of the polypeptide isoforms
(two the b1, one the b1b) or both isoforms (one change). The other
two unreported changes, one synonymous and one in the 39UTR,
show weaker hints of pathogenicity. The main clinical features of the
carrier subjects and molecular details of the six changes are reported
below and in Figure 1.
A previously unreported C.A transversion in exon 2, which we
interpreted as likely to be pathogenic, resulting in the substitution of
tyrosine for serine at position 15 of both SCN1B isoforms
(p.Ser15Tyr-SCN1B; p.Ser15Tyr-SCN1Bb), was identified in patient
1. The patient is a 52-year-old man with a spontaneous BrS type 1
ECG pattern in the 2nd intercostal space who also had a syncopal
episode at 35 years of age. He denied having palpitations, thoracic
pain, or seizures. His paternal uncle died suddenly at age 40. Serine
15 is predicted by the SignalP 4.1 algorithm (http://www.cbs.dtu.dk/
services/SignalP/) to belong to the signal peptide8,23. Five of the six
bioinformatic tools used in this study predicted that the amino acid
substitution would be benign. However, these methods may be of
limited use for changes in signal peptides because of the low sequence
conservation and lack of three-dimensional structure of these
regions. In fact, when considering the role of signal peptides in pro-
tein biosynthesis, the substitution of a serine with a bulkier tyrosine is
expected to affect the processing of the precursor polypeptide chains
and to result in deficiency of both b1 isoforms23. Additionally, the
absence of this variant in the Exome Sequencing Project (ESP)24
population, and in 1000 Genomes25, supports its pathogenicity.
A synonymous G.A transition in exon 3A that we considered to
be of unknown significance (p.Gly196Gly-SCN1Bb) was identified in
patient 2. He is a 50-year-old man with BrS type 2 ECG at baseline.
Spontaneous BrS type 1 ECG was documented via 12-lead 24-hour
Holter monitoring. The death of his father at 32 years of age was
Figure 1 | The diagnostic ECG of the six patients who were carriers of an SCN1B variant. Patients #1, #2 and #3 had a spontaneous type 1 pattern, while
patients #4, #5 and #6 had type 1 ECG induced during ajmaline test. Cardiac conduction properties in patients with SCN1Bmutation were always in the
normal range. HV intervals and PR andQRS intervals at ECG are reported here. Patients: HV interval (ms); PR (ms); QRS (ms). Patient #1: not available;
160; 80. Patient #2: 37; 160; 80. Patient #3: 43; 160; 80. Patient #4: 48; 160; 80. Patient #5: not available; 180; 80. Patient #6: 45; 200; 90. No patient had
pauses observed at Holter monitoring.
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ascribed to valvular heart disease. In view of the mounting evidence
of the contribution of synonymous variants to human disease26, we
considered the possibility that the variant may affect splicing, mRNA
stability or exerts a different pathogenic effect. These latter scenarios
are still possible despite the fact that in silico programs did not predict
any effect on the splicing function. Notably also this variant was
absent in control populations.
A likely pathogenic G.A transition in exon 3A (p.Arg214Gln-
SCN1Bb) was identified in patient 3, a 58-year-old woman with BrS
type 1 ECG at baseline, who experienced a syncopal episode during
emesis. This variant has previously been described in patients affec-
ted by BrS6,16,18,22 as well as in cases of SIDS16, lone atrial fibrillation18,
and various neurological disorders11. It also has been reported in the
dbSNP, ESP (23 out of 6956 alleles) and 1000 Genomes (MAF5
0.1%) databases. Further evidence that this variant may indeed be
pathogenic, even if observed in the general population, comes from
functional studies. Co-expression of mutant p.Arg214Gln-SCN1Bb
with SCN5A/WT orKCND3/WTwas shown to result in a decrease in
the peak of sodium current density and an increase in the transient
outward potassium current (Ito), respectively, compared with the
wild-type16.
A new rare variant that we considered likely to be pathogenic
was found at the exon/intron 4 junction, a C.A transversion
resulting in the substitution of aspartate for alanine at position
197 of the SCN1B transcript. It was identified in a 35-year-old
man who experienced two episodes of neuromediated syncope
after having a cough (patient 4). His baseline ECG showed a
2 mm J point elevation in V2 and BrS type 1 pattern was observed
during ajmaline challenge. Head-up tilt test showed cardio-inhib-
itory syncope. Programmed electrical stimulation did not induce
ventricular arrhythmias. A loop recorder was implanted, which
documented sporadic sinus pauses (maximum duration 3.5 s)
without symptoms. The family history was negative for sudden
cardiac death and epilepsy. The predicted effect at the protein
level involves the transmembrane b1 isoform only (p.Ala197Asp-
SCN1B). As cytosine 590 is the last nucleotide of exon 4, it cannot
be excluded that substitution interferes with the splicing process
and results in a disruptive effect on both isoforms.
A likely pathogenic G.A transition in exon 5 (p.Cys211Tyr-
SCN1B) was identified in a 40-year-old man presenting with a BrS
type 3 ECG at baseline (patient 5). His medical history was unre-
markable. The patient denied having syncope, palpitations or sei-
zures. A BrS type 1 ECG pattern was induced by ajmaline testing.
There was no family history of sudden cardiac death or syncope. This
variant involves a highly conserved amino acid and was predicted to
be deleterious. It had not only been previously reported in a patient
with partial epileptic seizures27 but also in control individuals from
the same population and is present in the dbSNP, ESP (4 out of 13006
alleles) and 1000 Genomes databases (MAF50.1%). Considering the
reduced penetrance in BrS, a possible pathogenetic or modifying role
of this rare variant cannot be excluded.
A thymine for guanine substitution of unknown pathogenic sig-
nificance in the 39UTRof SCN1B isoformA (c.*76G.T-SCN1B) was
identified in a 48-year-old Colombian woman (patient 6). The
patient complained of arrhythmic palpitations occurring over the
last year that persisted for less than one hour. Her baseline ECG
showed a BrS type 3 pattern and type 1 ECG was induced in leads
V1 andV2 by ajmaline administration. During follow-up, the patient
exhibited a spontaneous BrS type 1 ECG pattern during 12-lead 24-
hour ECG recording. Ventricular arrhythmias were not induced
during the electrophysiological study. Because 39UTR is a known
target for gene regulation by microRNAs, the variant isoform A
could in some way alter protein synthesis. It should be noted that
the c.*76G.T variant is not reported in the 1000Genomes, while the
ESP database is not informative in this case because it does not
consider the 39UTR region.
Discussion
In the last few years, knowledge of causative factors and mechanisms
underlying BrS has mainly been focused on the SCN5A gene.
However, much less is known about the other BrS susceptibility
genes and several unsolved questions remain.
In this study we report our findings on the mutation screening of
the SCN1B gene, encoding an essential subunit of the sodium chan-
nel in 145 unrelated SCN5A-negative BrS patients from a single
centre registry. We found four likely pathogenic SCN1B variants,
two of which were previously undescribed, including p.Ser15Tyr,
which is to our knowledge the first reported signal peptide mutation
of SCN1B. In addition, two changes with weaker evidence of patho-
genicity were considered to be of unknown significance (Table 1).
Variants likely to be causative of BrS were observed with low
prevalence in SCN1B (2.75%), which is in agreement with previous
reports6,15,16,18,20–22.
The obviously low detection rate of putative SCN1B mutation is
not surprising, if one considers the small size of the SCN1B gene.
However, this may not be the only explanation because the propor-
tion of SCN1B/SCN1Bb mutations found among BrS patients in the
analysed DNA sequence of the gene (4 mutations/2866 bp) is half of
that found in the SCN5A sequence that we analysed in an equal
number of consecutive BrS patients (26/9576 bp - our unpublished
data).
At the time of clinical diagnosis, no other case of Brugada ECG
pattern was observed among the first-degree relatives of these six
families. This restrained us from referring them to genetic counsel-
ling and testing. Therefore, it was impossible to perform co-segrega-
tion studies to support or weaken the pathogenicity of the identified
changes. However, the absence of clinical signs of BrS indicates that
SCN1B variants, if pathogenic at all, have a low penetrance, in
accordance with previous studies6,15,16,18,22.
Within the limitations of a single gene analysis in a relatively small
number of patients, the spectrum of SCN1B variants identified in this
and previous studies can be interpreted by assuming that SCN1B
mutationsmay have a causative or amodifier role in the pathogenesis
of BrS. This and all previous studies have encompassed various mis-
sense changes as well as a null mutation and changes in noncoding
regions. Pathogenesis may involve a loss of function mechanism, as
established in the case of SCN5A28. This viewmay prompt functional
studies to verify whether both SCN5A and SCN1B mutations act
through a similar pathogenic derangement of the sodium channel,
resulting in an increased risk of arrhythmia.
In keeping with its tissue expression, several studies have assoc-
iated SCN1Bmutations not only with cardiac arrhythmias6,15,16,18,20–22
but also with various neurologic phenotypes including epilepsy9,12–14.
The mechanism underlying the development of either brain and/or
heart phenotypes is not known. A variety of genetic and non-genetic
factors29 such as temperature30, age, gender, and epigenetics, are
mentioned frequently as possible modulators of the clinical pheno-
types. To better investigate the variety of affected tissues and man-
ifestations -probably deriving from distinct molecular pathogenic
mechanisms- the bioinformatic approach should be extended to
consider also the structural role of the affected residues and pro-
tein-protein interactions. Furthermore, more advanced functional
studies based on cellular and animal models are needed; these should
employ the same approaches used to investigate the neurologic
SCN1B phenotypes9. The involvement of SCN1B in BrS underlines
the relevance of a careful analysis of ECG patterns and cardiological
symptoms in patients referred to neurology units. Conversely,
neurological symptoms should be considered carefully in patients
referred to cardiology units.
From a practical point of view, when a mixed cardiac and neuro-
logical phenotype is found, the patients should undergo SCN1B gen-
etic testing. However, no other special clinical signature shows up in
our study.
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In conclusion, our findings provide further evidence on the pre-
valence and type of the SCN1B variants.We also highlight the need to
describe these genetic variants in an unambiguous format, according
to the current nomenclature guidelines, as such clarity is necessary at
both the clinical and laboratory level, mainly in view of the intro-
duction of Next Generation Sequencing approaches in the molecular
diagnosis of BrS.
Methods
Study Subjects. The present study involves a cohort of 145 patients [115 males, mean
age 44 years (range 6.1–68.4), 30 females, mean age 47.8 years (range 9.4–75.7)]
referred to our Laboratory of Medical Genetics for genetic analysis. Most of the
patients belong to the Piedmont Brugada Registry31 established in 2001.
Every patient exhibited type 1 Brugada ECG pattern32 either spontaneous (43%) or
induced by sodium channel blockers (2/3 ajmaline, the remaining flecainide). Routine
examinations, including echocardiography, ruled out any underlying structural heart
disease. SCN5A testing by direct sequencing and MLPA (Multiplex Ligation-
dependent Probe Amplification) resulted negative in all participants.
Clinical information and blood samples were collected for diagnostic testing in
patients with spontaneous or drug-induced type 1 Brugada ECG. Part of the
remaining DNA sample extracted from blood was conserved for second level analysis
(i.e., screening of other candidate genes), depending on the specific written consent
obtained in occasion of the pre-test genetic counselling session.
Ethics Statement. Written informed consent was obtained from each participant.
Approval was obtained from the institutional review boards at the University of
TorinoMedical School. The study was carried out in compliance with the Helsinki
Declaration. The experimental protocol was carried out in accordance with the
approved guidelines.
SCN1B mutation screening. The entire SCN1B coding sequence, including the
alternatively spliced exon 3A and the 39UTR, was amplified using primers designed
on the flanking intronic or exonic sequences. Primers and PCR conditions are
available on request. Sanger sequencing was performed by an external commercial
service using standard protocols. Putative pathogenic variants were validated via
bidirectional re-sequencing of an independent PCR amplification.
As approval of the SCN1B sequence in the Locus Reference Genomic33 website is
still pending, variants were numbered according to the NM_0011037, NP_001028
(SCN1B isoform A) and NM_199037, NP_950238 (SCN1B isoform B) RefSeqs from
the Genome Reference ConsortiumHuman Build 37.3 (NC_000019.9) and described
according to the Human Genome Variation Society guidelines34.
Variants characterization and bioinformatics. Each variant was classified as neutral
polymorphism, putatively pathogenic, or of unknown pathogenicity. This
classification was achieved by considering the following: (1) the reported frequency in
the following databases: dbSNP (build 131; http://www.ncbi.nlm.nih.gov/projects/
SNP/), HGMDH(http://www.biobase-international.com/product/hgmd), 1000
Genomes (http://www.1000genomes.org/), NHLBI GO ESP (http://evs.gs.
washington.edu/EVS/) [date (06, 2014) accessed]; (2) literature reports of presence in
patients or healthy subjects; (3) evolutionary conservation of the involved residue at
both nucleotide and amino acid level, calculated by multiple alignments of 46
vertebrate species and (4) in silico prediction of functional effect by SIFT (http://sift.
jcvi.org/), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), SNAP (http://
rostlab.org/services/snap/), SNPs3D (http://www.snps3d.org/), Panther (http://
www.pantherdb.org/), MutPred (http://mutpred.mutdb.org/), NetGene (http://
www.cbs.dtu.dk/services/NetGene2/), Splice View (http://zeus2.itb.cnr.it/
,webgene/wwwspliceview_ex.html) and NNSplice (http://www.fruitfly.org/seq_
tools/splice.html).
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